Human Plasma In-Cell Western Assays-An In vitro Predictor for In vivo Pharmacology in Oncology Drug Discovery.

drug discovery in vivo potency in-cell Western plasma protein binding

Journal

Current protocols
ISSN: 2691-1299
Titre abrégé: Curr Protoc
Pays: United States
ID NLM: 101773894

Informations de publication

Date de publication:
Feb 2021
Historique:
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 22 6 2021
Statut: ppublish

Résumé

Evaluation of in vivo potencies plays an important role in drug discovery. Traditionally, the cellular activity and percent of plasma protein binding of a test agent are evaluated separately, with the plasma protein binding-adjusted cellular potency computation used to estimate in vivo potency. This process is costly, takes weeks to complete, and is increasingly unreliable for compounds that bind extensively to plasma proteins. Described in this article is a simple, high-throughput human plasma in-cell Western (ICW) assay that directly incorporates plasma protein binding into a cellular pharmacodynamic assay to provide a rapid and accurate estimate of in vivo potencies. The assay is versatile and can be readily employed for various targets that require short treatment periods for displaying maximal biological responses. © 2021 Wiley Periodicals LLC. Basic Protocol: Concentration-dependent human plasma ICW assay to determine test compound IC

Identifiants

pubmed: 33587334
doi: 10.1002/cpz1.51
doi:

Substances chimiques

Blood Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e51

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Bohnert, T., & Gan, L. S. (2013). Plasma protein binding: From discovery to development. Journal of Pharmaceutical Sciences, 102(9), 2953-2994. doi: 10.1002/jps.23614.
Boveia, V., & Schutz-Geschwender, A. (2015). Quantitative analysis of signal transduction with In-Cell Western immunofluorescence assays. Methods in Molecular Biology, 1314, 115-130. doi: 10.1007/978-1-4939-2718-0_13.
Chen, H., Kovar, J., Sissons, S., Cox, K., Matter, W., Chadwell, F., … Olive, D. M. (2005). A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Analytical Biochemistry, 338(1), 136-142. doi: 10.1016/j.ab.2004.11.015.
Cidado, J., Boiko, S., Proia, T., Ferguson, D., Criscione, S. W., San Martin, M., … Drew, L. (2020). AZD4573 Is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells. Clinical Cancer Research, 26(4), 922-934. doi: 10.1158/1078-0432.CCR-19-1853.
Ferguson, F. M., & Gray, N. S. (2018). Kinase inhibitors: The road ahead. Nature Reviews Drug Discovery, 17(5), 353-377. doi: 10.1038/nrd.2018.21.
Howard, M. L., Hill, J. J., Galluppi, G. R., & McLean, M. A. (2010). Plasma protein binding in drug discovery and development. Combinatorial Chemistry & High Throughput Screening, 13(2), 170-187. doi: 10.2174/138620710790596745.
Phelan, K., & May, K. M. (2015). Basic techniques in mammalian cell tissue culture. Current Protocols in Cell Biology, 66, 1.1.1-1.1.22. doi: 10.1002/0471143030.cb0101s66.
Smith, D. A., Di, L., & Kerns, E. H. (2010). The effect of plasma protein binding on in vivo efficacy: Misconceptions in drug discovery. Nature Reviews Drug Discovery, 9(12), 929-939. doi: 10.1038/nrd3287.
Trainor, G. L. (2007). The importance of plasma protein binding in drug discovery. Expert Opinion on Drug Discovery, 2(1), 51-64. doi: 10.1517/17460441.2.1.51.
Wong, S. K. (2004). A 384-well cell-based phospho-ERK assay for dopamine D2 and D3 receptors. Analytical Biochemistry, 333(2), 265-272. doi: 10.1016/j.ab.2004.05.011.
Yim, D. S. (2019). Potency and plasma protein binding of drugs in vitro: A potentially misleading pair for predicting in vivo efficacious concentrations in humans. The Korean Journal of Physiology & Pharmacology, 23(4), 231-236. doi: 10.4196/kjpp.2019.23.4.231.
Zhang, J., Yang, P. L., & Gray, N. S. (2009). Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 9(1), 28-39. doi: 10.1038/nrc2559.
Zhang, J. H., Chung, T. D., & Oldenburg, K. R. (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. Journal of Biomolecular Screening, 4(2), 67-73. doi: 10.1177/108705719900400206.

Auteurs

Yang W Zhang (YW)

Prelude Therapeutics, Wilmington, Delaware.

Kirsten Gallagher (K)

Prelude Therapeutics, Wilmington, Delaware.

Dimitrios Angelis (D)

Locanabio, Inc., San Diego, California.

Dave Rominger (D)

Prelude Therapeutics, Wilmington, Delaware.

Peggy Scherle (P)

Prelude Therapeutics, Wilmington, Delaware.

Kris Vaddi (K)

Prelude Therapeutics, Wilmington, Delaware.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH